Published in Stat Med on November 27, 2016
The BUGS project: Evolution, critique and future directions. Stat Med (2009) 11.19
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2011) 4.31
Design and analysis of phase I clinical trials. Biometrics (1989) 4.31
Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med (1998) 4.19
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Dose-finding designs for HIV studies. Biometrics (2001) 2.22
Adaptive trial designs: a review of barriers and opportunities. Trials (2012) 1.91
The continual reassessment method for dose-finding studies: a tutorial. Clin Trials (2006) 1.79
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat (1994) 1.54
ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clin Trials (2005) 1.42
High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis (2009) 1.10
Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther (2004) 0.94
The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters. AIDS (1999) 0.93
Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Clin Trials (2008) 0.84
Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol (2013) 0.83
A Bayesian dose finding design for dual endpoint phase I trials. Stat Med (2006) 0.81
Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat (2012) 0.79